Rafael Holdings, Inc. (RFL) News
Follow Rafael Holdings, Inc. (RFL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Rafael Holdings Reports FY 2026 Revenue of $874K, Net Loss of $29.6M
The company’s attributable net loss narrowed from $30.5 million a year earlier, while its consolidated net loss was $28 million. Operating loss widened to $33.4 million.
EARNINGS | Oct 29, 2026, 03:45 PM UTC
M
Rafael Holdings reports Q4 net loss
Rafael Holdings reported Q4 operating income of USD -9.731 million.
EQUITY | Oct 29, 2026, 12:20 PM UTC
M
Rafael Holdings Reports Q4 Revenue of $244,000
EQUITY | Oct 29, 2026, 12:11 PM UTC
H
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling over 200 points on Wednesday. The Dow traded down 0.42% to 51,135.81 while the NASDAQ rose 0.86% to 27,028.35. The S&P 500 also rose, g
LIVE | Sep 30, 2026, 07:18 PM UTC
H
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.09% to 51,398.68 while the NASDAQ rose 0.48% to 26,926.8
LIVE | Sep 30, 2026, 01:42 PM UTC
L
Rafael Holdings reports Phase 3 topline: prespecified subgroup meets significance; NDA on track
Rafael Holdings announced Phase 3 topline results for Trappsol Cyclo showing a non-significant primary result but a significant benefit in patients on background miglustat/leucine.Key Highlights:Original SEC Filing: Rafa
REGULATION | Sep 30, 2026, 11:33 AM UTC
L
Rafael Holdings, Inc. (RFL) Phase 3 Misses Primary Endpoint; Subgroup Met Significance
Rafael Holdings reported Trappsol Cyclo’s Phase 3 did not reach statistical significance on the primary endpoint, while a prespecified subgroup on miglustat and/or leucine showed a statistically significant effect. The c
NEWS | Sep 30, 2026, 11:08 AM UTC
L
Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Rafael Holdings Inc NYSE:RFL
NEWS | Sep 30, 2026, 11:06 AM UTC